October 31, 2025

Single-Injection Omvoh Option Simplifies Ulcerative Colitis Care

The FDA approved Eli Lilly’s interleukin-23p19 antagonist Omvoh (mirikizumab-mrkz) as a once-monthly single-injection maintenance option for adults with moderately to severely active ulcerative colitis.

Conexiant

October 31, 2025

EU Approval for OFA® Analyzer

The CE Mark certification of Konan Medical’s OFA marks a revolution in objective visual testing in Europe, enhancing patient care.

The Ophthalmologist

October 30, 2025

Summarizing the Big Events in the Small Molecules Field

October 2025 highlights in the small molecules sector include developments in dermatitis treatment, improvements in epilepsy symptoms, and the effects of amoxicillin availability.

The Medicine Maker

October 29, 2025

FDA Pushes Faster, Cheaper Route for Biosimilar Approval

The FDA released new draft guidance to streamline biosimilar development.

Conexiant

October 29, 2025

H-1B Visa Changes: Who Pays the Price?

New fee structure could hit hardest where physicians are needed most.

Conexiant

October 27, 2025

State to End Vaccine Mandates — What Then?

After decades of required shots, Florida plans to make school immunizations optional — and experts stay quiet.

KFF Health News

October 24, 2025

Elinzanetant Approved for Menopausal Hot Flashes by FDA

Bayer’s dual neurokinin 1 and 3 receptor antagonist elinzanetant (Lynkuet) reduced the frequency and severity of menopausal vasomotor symptoms in phase 3 OASIS trials, providing a once daily, nonhormonal treatment option for moderate to severe hot flashes.

Conexiant

October 22, 2025

Fall Vaccines: What’s New, What’s Not

Updated CDC fall vaccine guidance simplifies covid, flu, and RSV shots with broad access and minimal changes from last year.

KFF Health News

October 22, 2025

FDA Redefining Depression Treatment with New Approvals?

Researchers analyze FDA-approved and Phase 3 antidepressants from 2009 to 2025.

Conexiant